Promiscuous labeling enzymes, such as APEX2 or TurboID, are commonly used in in situ biotinylation studies of subcellular proteomes or protein-protein interactions. Although the conventional approach of enriching biotinylated proteins is widely implemented, in-depth identification of specific biotinylation sites remains challenging, and current approaches are technically demanding with low yields. ... More
Kinetic reaction modeling for antibody-drug conjugate process development.
AuthorsAndris S,Seidel J,Hubbuch J
JournalJournal of biotechnology
PubMed ID31557498
By combining the specificity of monoclonal antibodies (mAbs) and the efficacy of cytotoxic drugs in one molecule, antibody-drug conjugates (ADCs) form a promising class of anti-cancer therapeutics. This is emphasized by around 65 molecules in clinical trials and four marketed products. The conjugation reaction of mAbs with small-molecule drugs is ... More
The impact of glycosylation on monoclonal antibody conformation and stability.
AuthorsZheng K,Bantog C,Bayer R
JournalmAbs
PubMed ID22123061
Antibody glycosylation is a common post-translational modification and has a critical role in antibody effector function. The use of glycoengineering to produce antibodies with specific glycoforms may be required to achieve the desired therapeutic efficacy. However, the modified molecule could have unusual behavior during development due to the alteration of ... More
Automated multi-attribute method sample preparation using high-throughput buffer exchange tips.
JournalRapid communications in mass spectrometry : RCM
PubMed ID34783086
RATIONALE: The multi-attribute method (MAM) has become a valuable mass spectrometry (MS)-based tool that can identify and quantify the site-specific product attributes and purity information for biotherapeutics such as monoclonal antibodies (mAbs) and fusion molecules in recent years. As we expand the use of the MAM at various stages of ... More